SL30049: Cancer therapeutics
[Page last updated: 03 June 2024]
Academic Year: | 2024/25 |
Owning Department/School: | Department of Life Sciences |
Credits: | 6 [equivalent to 12 CATS credits] |
Notional Study Hours: | 120 |
Level: | Honours (FHEQ level 6) |
Period: |
|
Assessment Summary: | CW 100% |
Assessment Detail: |
|
Supplementary Assessment: |
|
Requisites: | Before taking this module you are advised to take BB20023 OR take SL20003 |
Learning Outcomes: |
After taking this course the student should be able to:
* Demonstrate a thorough knowledge of the molecular and microenvironmental differences between cancer and normal tissues * Explain how these differences are exploited in drug design for cancer treatment * Critically evaluate current and emerging therapies against cancer. |
Aims: | To provide students with:
* A thorough understanding of the scientific basis underlying the principles and practice of cancer therapeutics * A critical overview of the biology behind the development and evaluation of current and emerging treatments for cancer. |
Skills: | Learning and studying T/F/A, information handling and retrieval T/F/A, working independently T/F, written communication T/F/A, oral communication T/F/A. |
Content: | Molecular and cellular cancer pathways associated with the tumour microenvironment or growth, which underpin current cancer treatments including;
* Genetic screening * Radiotherapy, chemotherapy and adjuvant therapies * Emerging therapies such as immunotherapy, angiotherapy and other small molecule therapies based on the translation of innovative cancer biology research into lead and preclinical stage drug candidates. |
Course availability: |
SL30049 is Optional on the following courses:Department of Life Sciences
|
Notes:
|